
Dexter Surgical Robot by Distalmotion Gains FDA Approval

Share this article
Distalmotion’s Dexter Surgical Robot has officially received FDA approval for use in inguinal hernia repairs, introducing a transformative solution for outpatient surgery and Ambulatory Surgery Centers (ASCs) in the U.S. Known for its compact and mobile design, Dexter is set to meet the rising demand for cost-effective, robotic-assisted surgeries in high-volume settings.
Dexter, with over 1,300 European cases, brings the advantages of robotic surgery to high-volume, cost-sensitive ASCs. Its compact, mobile design optimizes space and minimizes costs, making it accessible for a wider range of facilities. Dexter integrates seamlessly into current OR setups, avoiding workflow disruptions and using single-use instruments to eliminate reprocessing.
CEO Greg Roche highlights Dexter’s role in bridging cost and space barriers, enhancing care without altering surgical teams’ methods. Dexter’s ergonomic, open platform enables smooth transitions between console and bedside, giving surgeons direct patient access and flexibility in choosing tools and techniques. Several surgeons praise Dexter’s intuitive design and adaptable setup for outpatient procedures. Dexter supports versatile 3D imaging and energy devices, expanding robotic-assisted surgery accessibility and defining a new standard for minimally invasive care.
Distalmotion is a Swiss-based medical device company focused on developing and providing robotic solutions for minimally invasive surgeries. Founded and headquartered in Lausanne, Switzerland, Distalmotion’s mission is to make robotic surgery more accessible and efficient for hospitals, outpatient centers, and ambulatory surgery centers (ASCs).
➡️ Source: Press release
📸 © Distalmotion